Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

6,512

datasets available to search

ShareScore release 0.7.1

Reset

Dataset results

6,512 results for “clinical trial”

Learn how ShareScore rates datasets ↗
zenodo40/100

Loss of socioemotional and occupational roles in people with Long COVID according to sociodemographic and clinical factors: Secondary data from Randomized Clinical Trial.

<p>This is a&nbsp;cross-sectional study was carried out with the participation of 100 patients diagnosed with Long-COVID, over 18 years of age and attended by Primary Health Care in the Autonomous Community of Aragon.&nbsp;The purpose of this study is to analyse the loss of socioemotional and occupational roles that people with Long COVID have suffered in their lives as a consequence of the disease. As a secondary objective, it was proposed to analyze the sociodemographic and clinical factors associated with this loss of roles. The main study variable was the loss of significant socioemotional and occupational roles of the participants. Sociodemographic and clinical data were also collected through a structured interview.</p>

opencc-by-4.0Aug 2023View details →
zenodo40/100

Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence

<p>We used two different methodologies of generative artificial intelligence, CTAB-GAN+ and normalizing flows (NFlow), to synthesize patient data based on 1606 patients with acute myeloid leukemia that were treated within four multicenter clinical trials. The resulting data set consists of 1606 synthetic patients for each of the models.</p> <p>This dataset is associated with our publication "Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence" by Eckardt et al., npj Digital Medicine, 2024 (<a href="https://doi.org/10.1038/s41746-024-01076-x" target="_new">https://doi.org/10.1038/s41746-024-01076-x</a>). If you use this dataset, please cite our paper.</p> <p>&nbsp;</p> <p><strong>Data Dictionary</strong></p> <table> <tbody><tr> <th>NAME</th> <th>LABEL</th> <th>TYPE</th> <th>CODELIST</th> </tr> </tbody><tbody> <tr> <td>AGE</td> <td>age</td> <td>num</td> <td>in years</td> </tr> <tr> <td>AMLSTAT</td> <td>AML status</td> <td>char</td> <td>de novo, sAML, tAML</td> </tr> <tr> <td>ASXL1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>ATRX</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>BCOR</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>BCORL1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>BRAF</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>CALR</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>CBL</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>CBLB</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>CDKN2A</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>CEBPA</td> <td>CEBPA mutation</td> <td>char</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>CGCX</td> <td>complex cytogenetic karyotype</td> <td>char</td> <td>0 'No', 1 'Yes'</td> </tr> <tr> <td>CGNK</td> <td>cytogenetic normal karyotype</td> <td>char</td> <td>0 'No', 1 'Yes'</td> </tr> <tr> <td>CR1</td> <td>first complete remission</td> <td>char</td> <td>0 = 'not achieved', 1 = 'achieved'</td> </tr> <tr> <td>CSF3R</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>CUX1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>DNMT3A</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>EFSSTAT</td> <td>status variable for EFSTM</td> <td>num</td> <td>0 'censored' 1 'event'</td> </tr> <tr> <td>EFSTM</td> <td>event free survival time</td> <td>num</td> <td>in months</td> </tr> <tr> <td>ETV6</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>EXAML</td> <td>extramedullary AML</td> <td>char</td> <td>0 'No', 1 'Yes'</td> </tr> <tr> <td>EZH2</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>FBXW7</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>FLT3I</td> <td>FLT3-ITD mutation status</td> <td>char</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>FLT3T</td> <td>FLT3-TKD mutation status</td> <td>char</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>GATA2</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>GNAS</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>HB</td> <td>hemoglobin</td> <td>num</td> <td>in mmol/l</td> </tr> <tr> <td>HRAS</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>IDH1</td> <td>IDH1 mutation status</td> <td>char</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>IDH2</td> <td>IDH2 mutation status</td> <td>char</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>IKZF1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>JAK2</td> <td>Jak2 Mutation</td> <td>char</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>KDM6A</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>KIT</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>KRAS</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>MPL</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>MYD88</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>NOTCH1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>NPM1</td> <td>NPM1 mutation status</td> <td>char</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>NRAS</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>OSSTAT</td> <td>status variable for OSTM</td> <td>num</td> <td>0 'censored' 1 'event'</td> </tr> <tr> <td>OSTM</td> <td>overall survival time</td> <td>num</td> <td>in months</td> </tr> <tr> <td>PDGFRA</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>PHF6</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>PLT</td> <td>platelet count</td> <td>num</td> <td>in 10⁶/l</td> </tr> <tr> <td>PTEN</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>PTPN11</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>RAD21</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>RUNX1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>SETBP1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>SEX</td> <td>sex</td> <td>char</td> <td>f 'female', m 'male'</td> </tr> <tr> <td>SF3B1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>SMC1A</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>SMC3</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>SRSF2</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>STAG2</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>SUBJID</td> <td>subject identifier</td> <td>char</td> <td>&nbsp;</td> </tr> <tr> <td>TET2</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>TP53</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>U2AF1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>WBC</td> <td>white blood count</td> <td>num</td> <td>in 10⁶/l</td> </tr> <tr> <td>WT1</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>ZRSR2</td> <td>mutation indicator, NGS</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>inv16_t16.16</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t8.21</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t.6.9..p23.q34.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>inv.3..q21.q26.2.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>minus.5</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>del.5q.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t.9.22..q34.q11.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>minus.7</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>minus.17</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t.v.11..v.q23.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>abn.17p.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t.9.11..p21.23.q23.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t.3.5.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t.6.11.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t.10.11.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>t.11.19..q23.p13.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>del.7q.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>del.9q.</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>trisomy 8</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>trisomy 21</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>minus.Y</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> <tr> <td>minus.X</td> <td>mutation indicator, cytogenetics</td> <td>num</td> <td>0 = 'no mutation', 1 = 'mutation'</td> </tr> </tbody> </table>

opencc-by-4.0Sep 2023View details →
ClinicalTrials.gov40/100

Clinical Trial to Assess the Effectiveness of Applying Dry Local Heat and/ or High Tourniquet Pressure for Venipuncture.

ClinicalTrials.gov study NCT04027218. IPD Sharing: YES. Countries: 1. Publications: 8.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

ClinicalTrials.gov study NCT03306277. IPD Sharing: YES. Countries: 1. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Clinical Trial of a Supporter-Targeted Intervention to Improve Outcomes in Recent Sexual Assault Survivors

ClinicalTrials.gov study NCT05345405. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Air-Q® SP Versus Air-Q® and I-gel: A Randomized Clinical Trial

ClinicalTrials.gov study NCT01592760. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov40/100

Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial

ClinicalTrials.gov study NCT03584854. IPD Sharing: YES. Countries: 1. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Internet-based Conversational Engagement Clinical Trial

ClinicalTrials.gov study NCT02871921. IPD Sharing: YES. Countries: 1. Publications: 9.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)

ClinicalTrials.gov study NCT01131312. IPD Sharing: YES. Countries: 1. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial

ClinicalTrials.gov study NCT02643381. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov40/100

Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

ClinicalTrials.gov study NCT03461289. IPD Sharing: YES. Countries: 4. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Connect-Home Clinical Trial

ClinicalTrials.gov study NCT03810534. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

ClinicalTrials.gov study NCT01636687. IPD Sharing: UNDECIDED. Countries: 5. Publications: 6.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad40/100

Randomized controlled clinical trials with tagged information regarding the number of participants

Open the record for dataset details and reuse information.

publicSep 2024View details →
dryad40/100

A web-based tool for automatically linking clinical trials to their publications - example calculation

Open the record for dataset details and reuse information.

publicJan 2022View details →
zenodo36/100

The effects of a clinically feasible application of low-level laser therapy on the rate of orthodontic tooth movement: A triple-blinded split-mouth randomized controlled clinical trial.

<p>Dataset for all study&#39;s analyses.</p>

opencc-by-4.0Aug 2019View details →
zenodo36/100

Raw data related to: Randomised Clinical Trial: Calorie Restriction Regimen with Tomato Juice Supplementation Ameliorates Oxidative Stress and Preserves a Proper Immune Surveillance Modulating Mitochondrial Bioenergetics of T-Lymphocytes in Obese Children Affected by Non-Alcoholic Fatty Liver Disease (NAFLD)

<p><strong>Abstract</strong></p> <p>Fatty liver disease is a serious complication of childhood obesity. Calorie-restricted regimen&nbsp;(RCR) is one of the e ective therapy for this condition. Aim of the study was to evaluate the effect&nbsp;of lycopene-rich tomato sauce with oregano and basil extracts in obese children with fatty liver on&nbsp;RCR. 61 obese children with fatty liver were enrolled, 52 completed the study. A randomized cross&nbsp;over clinical trial was performed. Participants were assigned to RCR alone or with a supplement of&nbsp;lycopene-rich tomato juice for 60 days; subsequently, the groups were switched to the alternative&nbsp;regimen for the next 60 days. Reduction in BMI, HOMA-IR, cholesterol, triglycerides, liver size,&nbsp;and steatosis was more profound in tomato-supplemented group. Leptin decreased in both groups&nbsp;whereas adiponectin raised only after tomato supplementation. RCR is associated with the impaired&nbsp;engagement of T-cells glycolysis and proliferation, tomato-supplementation resulted in glycolytic&nbsp;metabolic activation of T-cells. Tomato juice ameliorates glucose and lipid metabolism in obese&nbsp;children, improve oxidative and inflammatory state and modulates the mitochondrial metabolism&nbsp;of T-cells contributing to a maintenance of a proper immune surveillance in children, impaired by&nbsp;RCR. The addition of tomato to RCR could be considered a protective and preventive support to&nbsp;obese child.</p> <p><strong>Progetto giovani ricercatori&nbsp;</strong>[GR-2016-02363725] dal titolo: &quot;Immune Tolerance, Metabolism and Multiple Sclerosis: Novel Molecular Tools to Monitor Disease Pathogenesis and Progression&quot;</p>

opencc-by-4.0Mar 2020View details →
zenodo36/100

Dioxin Clinical Trials: Number of Studies per Condition

<p>As of May 2020, there were 15 reported clinical trials related to &ldquo;dioxin&rdquo; with 8 completed and 5 active studies.&nbsp;</p> <p>https://clinicaltrials.gov/</p>

opencc-by-4.0May 2020View details →
dryad36/100

Clinical trial generalizability assessment in the big data era: a review

<p><span><span><span>Clinical studies, especially randomized controlled trials, are essential for generating evidence for clinical practice.  However, generalizability is a long-standing concern when applying trial results to real-world patients.  Generalizability assessment is thus important, nevertheless, not consistently practiced.  We performed a systematic scoping review to understand the practice of generalizability assessment.  We identified 187 relevant papers and systematically organized these studies in a taxonomy with three dimensions: (1) data availability (i.e., before or after trial [<i>a priori</i> vs <i>a posteriori</i> generalizability]), (2) result outputs (i.e., score vs non-score), and (3) populations of interest.  We further reported disease areas, underrepresented subgroups, and types of data used to profile target populations.  We observed an increasing trend of generalizability assessments, but less than 30% of studies reported positive generalizability results.  As <i>a priori</i> generalizability can be assessed using only study design information (primarily eligibility criteria), it gives investigators a golden opportunity to adjust the study design before the trial starts.  Nevertheless, less than 40% of the studies in our review assessed <i>a priori</i> generalizability.  With the wide adoption of electronic health records systems, rich real-world patient databases are increasingly available for generalizability assessment; however, informatics tools are lacking to support the adoption of generalizability assessment practice.</span></span></span></p>

opencc-zeroApr 2020View details →
zenodo36/100

WHO International Clinical Trials Registry Platform (ICTRP), April 2015

<p>The World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) dataset, retrieved in April 2015.</p> <p>At the time of writing, the WHO ICTRP does not have any way for the general public to retrieve their complete dataset. They provided special access to us (ClinicalTrials.gov) to retrieve the data, and gave permission for us to make the data publicly available.</p> <p>We distinguish records (a trial as registered in a specific registry) and variants (different versions of a record within that registry). Only the EU Clinical Trials Register (EUCTR) has multiple variants for some records, one for each member state where the trial was registered.</p> <p>The dataset consists of 320,790 variants of 285,177 unique records from sixteen registries. Variants were retrieved one-at-a-time over the course of the first week of April, as requests took ~ 2 seconds each to resolve. A list of non-ClinicalTrials.gov records was provided by the WHO, and a list of ClinicalTrials.gov records was retrieved from ClinicalTrials.gov.</p>

opencc-zeroFeb 2016View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record